Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Antiparkinson agent (dopamine precursor + decarboxylase inhibitor)

Levodopa / Carbidopa

pms-Levodopa-Carbidopa

Dosage form
Tablet
Available strengths
100 mg / 10 mg, 100 mg / 25 mg, 250 mg / 25 mg (levodopa / carbidopa)
Drug class
Antiparkinson agent (dopamine precursor + decarboxylase inhibitor)
Common brand
pms-Levodopa-Carbidopa

Clinical overview. Levodopa and carbidopa is a combination antiparkinson medicine used to treat the symptoms of Parkinson's disease. Levodopa replenishes dopamine in the brain, while carbidopa reduces its breakdown outside the brain, allowing lower doses and fewer side effects like nausea. Common side effects include nausea, dizziness, and involuntary movements, while sudden sleep onset and mental health changes are important risks to watch for. It is taken multiple times daily and requires careful, individualized dose titration.

Indication

Common therapeutic uses

  • Levodopa and carbidopa is used to treat the symptoms of Parkinson's disease in adults.
  • It is not recommended for treating drug-induced extrapyramidal reactions (movement side effects caused by other medications).

Pregnancy

Risk assessment and monitoring considerations

  • The effects of levodopa and carbidopa on human pregnancy are not well established.
  • Levodopa and carbidopa combinations have caused visceral and skeletal malformations in animal studies.
  • Levodopa and carbidopa should only be used in pregnancy if the anticipated benefit to the mother justifies the potential risk to the fetus.

Breastfeeding

Infant exposure considerations

  • It is not known whether carbidopa passes into breast milk.
  • Levodopa has been detected in the breast milk of a nursing mother taking levodopa and carbidopa for Parkinson's disease.
  • Levodopa and carbidopa should not be given to breastfeeding women unless the expected benefit to the mother outweighs the potential risk to the infant.

Geriatrics

Dosing and tolerability considerations

  • Studies and clinical experience suggest that older adults respond to levodopa and carbidopa similarly to younger adults in terms of safety and effectiveness.
  • Dosing in older adults is individualized in the same stepwise way as in other adults.

Pediatrics

Use in children and adolescents

  • Safety and effectiveness of levodopa and carbidopa have not been established in patients under 18 years of age, and it is not authorized for pediatric use.

Dosage & Administration

Practical dosing and administration

  • For patients not previously treated with levodopa, therapy usually starts with one 100 mg/25 mg tablet three times daily, providing 75 mg of carbidopa per day; the dose may be increased by one tablet every three days until the best effect is reached without causing involuntary movements.
  • During the dose increase, doses should be spread out to at least four times a day, and most patients should not exceed 1500 mg of levodopa per day.
  • For patients switching from levodopa alone, levodopa must be stopped at least 12 hours before starting levodopa and carbidopa, which is then started at a dose providing about 20% of the previous levodopa dose, divided into four to six doses per day.
  • Once stabilized, maintenance therapy provides at least 70 to 100 mg of carbidopa per day; if more carbidopa is needed, the 100 mg/25 mg strength may replace the 100 mg/10 mg strength, and if more levodopa is needed, the 250 mg/25 mg strength may replace lower-dose tablets, increased by up to one tablet per day or every other day to a maximum of eight 250 mg/25 mg tablets daily.
  • Tablets should be swallowed whole with fluids and not chewed, divided, or crushed, since dividing along the score line may not give an exact half dose.
  • If a dose is missed, it should be taken as soon as possible unless it is almost time for the next dose, in which case the missed dose is skipped and the regular schedule resumed; doses should never be doubled.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Overdose of levodopa and carbidopa can cause involuntary movements (dyskinesias), which are an early sign of excess dosage and usually require dose reduction.
  • Vitamin B6 (pyridoxine) does not reverse the effects of an overdose, unlike overdose of levodopa taken alone.
  • Cardiac arrhythmias may occur, and heart rhythm should be monitored closely after a significant overdose.
  • There is no established experience with dialysis for levodopa and carbidopa overdose, so its usefulness is unknown.
  • General supportive care, including careful intravenous fluid administration and maintaining an open airway, is the mainstay of overdose management.

Common side effects

Frequently reported tolerability concerns

  • Nausea may occur, particularly early in treatment.
  • Involuntary movements (dyskinesias), such as jerking, twisting, or writhing movements, may occur and are often an early sign that the dose needs to be reduced.
  • Dizziness may occur.
  • Headache may occur.
  • Insomnia or other sleep disturbances, including vivid dreams, may occur.
  • Loss of appetite may occur.
  • Dry mouth or an altered sense of taste may occur.
  • Fatigue or a general feeling of weakness may occur.
  • Muscle cramps or twitching may occur.
  • Dark-coloured urine or sweat may occur and is harmless.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Levodopa and carbidopa can cause sudden onset of sleep without warning, including while driving, and patients should not drive or operate machinery until they know how the medication affects them.
  • Mental changes, including paranoid thinking, hallucinations, or psychotic episodes, may occur.
  • Depression, with or without suicidal thoughts, may develop and requires careful monitoring.
  • Impulse control disorders, such as compulsive gambling, hypersexuality, compulsive spending, or binge eating, have been reported.
  • A syndrome resembling neuroleptic malignant syndrome, with severe muscle rigidity, high fever, and altered consciousness, can occur if the dose is reduced abruptly or the drug is stopped suddenly.
  • Levodopa may activate a dormant malignant melanoma, so any new or changing skin lesions should be evaluated promptly.
  • Severe gastrointestinal bleeding related to peptic ulcer disease has been reported.
  • Blood disorders, including low white blood cell counts, hemolytic anemia, and low platelet counts, have been reported rarely.
  • Seizures may occur, particularly in patients with a prior seizure history.
  • Seek urgent medical attention for chest pain, fainting, severe confusion, high fever with muscle stiffness, or new suicidal thoughts.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with a history of heart attack or heart rhythm disturbances, with close cardiac monitoring during initial dosing.
  • Use with caution in patients with a history of peptic ulcer disease due to the risk of gastrointestinal bleeding.
  • Use with caution in patients with chronic wide-angle glaucoma, with regular monitoring of eye pressure.
  • Use with caution in patients with a history of seizures or conditions that lower the seizure threshold.
  • Use with caution in patients with past or current psychosis or a history of depression.
  • Use with caution in patients with suspicious or undiagnosed skin lesions or a personal history of melanoma.
  • Use with caution in patients undergoing general anesthesia; therapy can generally continue as long as the patient can take fluids and medication by mouth.
  • Periodic monitoring of liver, blood, heart, and kidney function is recommended during long-term therapy.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with a known hypersensitivity to levodopa, carbidopa, or any ingredient in the formulation.
  • Contraindicated in patients taking nonselective monoamine oxidase inhibitors (MAOIs), which must be stopped at least two weeks before starting therapy.
  • Contraindicated in patients with uncontrolled cardiovascular, endocrine, blood, liver, lung (including asthma), or kidney disease.
  • Contraindicated in patients with narrow-angle glaucoma.
  • Contraindicated in patients for whom sympathomimetic amines, such as epinephrine or amphetamines, are contraindicated.
  • Contraindicated in patients with suspicious undiagnosed skin lesions or a history of melanoma.

Drug interactions

Clinically relevant combinations

  • Nonselective MAOIs must not be used with levodopa and carbidopa; selective MAO type B inhibitors, such as selegiline, may be used cautiously at recommended doses.
  • Antihypertensive drugs can cause an exaggerated drop in blood pressure (postural hypotension) when combined with levodopa and carbidopa, requiring dose adjustment.
  • Dopamine D2 receptor blockers, including certain antipsychotics and antinausea drugs, may reduce the effectiveness of levodopa.
  • Selegiline combined with levodopa and carbidopa has been associated with severe drops in blood pressure on standing.
  • Tricyclic antidepressants have rarely been associated with high blood pressure and dyskinesia when combined with levodopa and carbidopa.
  • Dopamine-depleting drugs, such as reserpine and tetrabenazine, are not recommended with levodopa and carbidopa because they reduce its effectiveness.
  • Isoniazid may reduce the effectiveness of levodopa and requires careful monitoring.
  • Iron supplements and iron-containing multivitamins can reduce absorption of levodopa and carbidopa.
  • Metoclopramide may increase levodopa absorption but can also worsen Parkinson's disease control through its own dopamine-blocking effect.
  • Levodopa and carbidopa may need to be discontinued the night before general anesthesia and resumed once the patient can take oral medication again.

Food interactions

Meal-related administration

  • Levodopa and carbidopa can be taken with or without food.
  • Since levodopa competes with certain amino acids for absorption, a high-protein meal taken at the same time may reduce how much levodopa is absorbed, so patients on a high-protein diet may benefit from spacing doses away from protein-rich meals.

Time of administration

Practical scheduling

  • Levodopa and carbidopa tablets can be taken at any time of day, with or without food, though consistent timing relative to meals may help patients on a high-protein diet maintain steady absorption.
  • Doses are typically spread across the day (three or more times daily) to maintain a consistent effect and reduce the "on-off" fluctuations sometimes seen with Parkinson's disease.

Storage

Product handling

  • Store levodopa and carbidopa tablets at room temperature (15°C to 30°C) in a well-closed container, protected from light and moisture.

Patient take-away

Key counselling points for a quick closing summary

  • Levodopa and carbidopa can suddenly cause you to fall asleep without warning, so do not drive or use machinery until you know how it affects you.
  • Take levodopa and carbidopa tablets whole with fluids; do not chew, crush, or split them, even along the score line.
  • Tell your healthcare professional right away if you notice new or worsening involuntary movements, mood changes, or thoughts of suicide.
  • Never stop levodopa and carbidopa abruptly or skip doses without talking to your healthcare professional first, as sudden changes can cause serious symptoms.
  • Report any new or changing skin spots or moles to your healthcare professional promptly.

References

Source material and product information

  1. Health Canada Product Monograph — Levodopa / Carbidopa

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.